A randomized, multicenter, double-blind, placebo-controlled, dose-range-finding, parallel-design, phase 2 trial of oral linaclotide acetate administered to patients with irritable bowel syndrome with constipation.
Latest Information Update: 21 Dec 2021
At a glance
- Drugs Linaclotide (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Ironwood Pharmaceuticals
- 27 Oct 2021 Results pooled analysis (of data pooled from NCT00460811, NCT00948818, NCT00938717, and NCT03573908 studies assessing symptoms of Irritable Bowel Syndrome With constipation presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
- 27 Oct 2021 Results of a pooled analysis (of data pooled from NCT00460811, NCT00948818, NCT00938717, and NCT03573908 studies) assessing for abdominal pain, discomfort, and bloating, and the temporal relationship between abdominal symptom and stool frequency responses presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
- 27 Oct 2010 Results were presented at the 18th United European Gastroenterology Week.